Hepatitis Delta virus in migrants: The challenge of elimination (ANRS CO22 HEPATHER cohort)

Autor: Fabienne Marcellin, Lauren Perières, Hélène Fontaine, Patrizia Carrieri, Morgane Bureau-Stoltmann, Stanislas Pol, Fabrice Carrat, Marta Lotto, Fabien Zoulim
Přispěvatelé: Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des sciences de la santé publique [Marseille] (ISSPAM), Département d'hépatologie [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie du système immunitaire (Inserm U1223), Institut Pasteur [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Service de santé publique [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), The cohort HEPATHER received financial support from the INSERM_ANRS MIE (France Recherche Nord & Sud Sida-VIH Hépatites, Maladies Infectieuses Emergentes), the French ANR (Agence Nationale de la recherché) Equipex and Cohort, the French DGS (Direction générale de la Santé), Merck Sharp and Dohme, Janssen, Gilead, Abbvie, Bristol-Myers Squibb and Roche., ANR-19-COHO-0002,Hepather (COHORTES),Therapeutic options for hepatitis B and/or C: a French nationwide cohort study(2019), Institut Pasteur [Paris] (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)
Rok vydání: 2021
Předmět:
medicine.medical_specialty
Cirrhosis
interquartile range
viruses
[SDV]Life Sciences [q-bio]
Population
BLV
medicine.disease_cause
treatment adherence
European centre for disease prevention and control
Virus
Chronic Hepatitis Delta
ECDC
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
Internal medicine
HDV
medicine
Risk of mortality
HBV
Humans
HCC
education
Hepatitis B virus
Transients and Migrants
Harm reduction
education.field_of_study
vulnerabilities
Hepatology
Virus de l'immunodéficience humaine
business.industry
Coinfection
National Reference Centres
IQR
migrants precarity
virus diseases
VIH
hepatocellular carcinoma
medicine.disease
Hepatitis B
digestive system diseases
CHD
Hepatocellular carcinoma
Cohort
Quality of Life
CNR
Bulevirtide
Hepatitis Delta Virus
business
hepatitis B virus
Zdroj: Liver International
Liver International, Wiley-Blackwell, 2021, 42, pp.249-252. ⟨10.1111/liv.15106⟩
Liver International, 2021, 42 (1), pp.249-252. ⟨10.1111/liv.15106⟩
ISSN: 1478-3231
1478-3223
DOI: 10.1111/liv.15106⟩
Popis: International audience; Novel treatments for hepatitis Delta virus (HDV) infection provide promising opportunities to treat patients with hepatitis B virus (HBV) and HDV co-infection. However, current clinical trials on HDV treatment rarely explore patients’ barriers to treatments. In Europe, HDV infection mostly affects young migrants from HDV-endemic areas who experience early liver-related mortality. Migrants are more likely to face multiple situations of statutory and socioeconomic insecurity and structural barriers than non-migrants. These obstacles may impact their quality of life and can (i) lead them to give secondary importance to certain HDV care options, (ii) delay treatment initiation and (iii) affect their adherence and commitment to care. Preliminary results from the ANRS CO22 HEPATHER cohort show that the majority (61.6%) of HBV-HDV co-infected migrants live in poverty. Moreover, half were diagnosed and a quarter of those who initiated HBV treatment had been in France for no more than two years, a period when language skills are often still poor and when knowledge of the health and administrative system may be lacking. We advocate for increased social science research, in particular qualitative studies, to investigate the effects that multiple forms of precarity (weak access to social rights, language barriers, housing insecurity, unexpected expenditures and other difficulties) may have on HDV screening opportunities, follow-up, and treatment pathways in migrants. This will help adapt communication and care around viral hepatitis, as well as inform and orient medical services and public health actors about the difficulties that migrants encounter.
Databáze: OpenAIRE
Externí odkaz: